Lung Diseases: Clinical Trials

4,990 trials for Lung Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2593 completed, 686 terminated, 582 recruiting, 464 unknown. 4990 Phase 1, 1634 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14990Completed 2593, Terminated 686, Recruiting 582, Unknown 464, Active not recruiting 290, Withdrawn 218, Not yet recruiting 126, Suspended 24, Enrolling by invitation 7
Phase 21634Completed 668, Recruiting 266, Terminated 237, Unknown 207, Active not recruiting 108, Withdrawn 90, Not yet recruiting 47, Suspended 8, Enrolling by invitation 3

Follow Lung Diseases: new trials by email Literature Review of Lung Diseases trials Research Report on Lung Diseases

Trials (filtered) newest first · largest first

All 4,990 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingRemeGen Co., Ltd.262027-12-012026-09-22
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets
MN-08 24 mg/day, MN-08 60 mg/day - Pulmonary Arterial Hypertension
Phase 1Not yet recruitingGuangzhou Magpie Pharmaceuticals Co., Ltd.162027-09-012026-09-14
cfMSC Stem Cell Therapy Targeting COPD
clonal fetal MSCs - Chronic Obstructive Pulmonary Disease (COPD)
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02
Antigen-specific T Cells Against Lung Cancer
Lung cancer-specific T cells - Lung Cancer
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute202027-06-012026-11-02
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer
Phase 1SuspendedUNC Lineberger Comprehensive Cancer Center62027-05-202026-04-23
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
Zanidatamab, Zongertinib - Non Small Cell Lung Cancer
Phase 1Not yet recruitingM.D. Anderson Cancer Center242027-04-012026-10-28
Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI
Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung
Phase 1 / Phase 2Not yet recruitingXemed LLC102027-03-012026-09-01
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
Metformin - Chronic Obstructive Pulmonary Disease (COPD)
Phase 1Not yet recruitingDuke University452027-02-012026-11-03
Little Lungs Study
Calfactant, Budesonide - Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Phase 1 / Phase 2Not yet recruitingUniversity of Wisconsin, Madison242027-02-012026-11-02
DK222 Study at Hopkins
[18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer
Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins62027-01-312026-09-29
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer
Phase 1SuspendedUniversity of Maryland, Baltimore502027-01-302026-09-14
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial
Phase 1Not yet recruitingGlaxoSmithKline602027-01-252026-07-16
Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer
NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 1 / Phase 2Not yet recruitingNob Hill Therapeutics, Inc.1002027-01-112026-10-08
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingMisty Shields162027-01-012026-10-15
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19
Phase 1 / Phase 2Not yet recruitingKimera Labs Inc.642027-01-012026-06-24
Taurine Supplementation in Adolescents With Post-COVID Condition
Taurine - Long COVID, Post COVID-19 Condition
Phase 1 / Phase 2Not yet recruitingUniversity of Alberta302026-12-302026-10-16
Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension
Protek Solo Transseptal Cannula - Lung Transplant, Pulmonary Hypertension
Phase 1RecruitingMayo Clinic42026-12-112026-07-31
Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer
Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss
Phase 1 / Phase 2Not yet recruitingVA Office of Research and Development432026-12-072026-11-12
3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial
3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping, 3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping - Non Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingSt. Joseph's Healthcare Hamilton892026-12-012026-02-02
The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD
Inhaled Nitric Oxide, Placebo - Chronic Obstructive Pulmonary Disease
Phase 1 / Phase 2Not yet recruitingUniversity of Alberta802026-12-012026-07-08

Showing 20 of 4990. Sign in to see all of them.

Narrower conditions

Carcinoma, Non-Small-Cell Lung (1978)  ·  Lung Neoplasms (867)  ·  COVID-19 (675)  ·  Colorectal Neoplasms (402)  ·  Asthma (399)  ·  Small Cell Lung Carcinoma (398)  ·  Neoplasms (360)  ·  Pulmonary Disease, Chronic Obstructive (353)  ·  Breast Neoplasms (351)  ·  Melanoma (340)  ·  Ovarian Neoplasms (327)  ·  Pancreatic Neoplasms (268)  ·  Neoplasm Metastasis (259)  ·  Squamous Cell Carcinoma of Head and Neck (255)  ·  Stomach Neoplasms (247)

Broader conditions

Respiratory Tract Diseases (4946)  ·  Neoplasms by Site (2686)  ·  Respiratory Tract Neoplasms (2674)  ·  Thoracic Neoplasms (2668)  ·  Neoplasms (2380)  ·  Bronchial Neoplasms (2222)  ·  Carcinoma, Bronchogenic (2221)  ·  Lung Neoplasms (1826)  ·  Neoplasms by Histologic Type (1059)  ·  Digestive System Diseases (1007)  ·  Pathological Conditions, Signs and Symptoms (979)  ·  Infections (931)  ·  Pathologic Processes (918)  ·  Neoplasms, Glandular and Epithelial (868)

Interventions

pembrolizumab (274)  ·  Carboplatin (236)  ·  Cisplatin (182)  ·  Pemetrexed (162)  ·  Paclitaxel (137)  ·  Nivolumab (134)  ·  Docetaxel (113)  ·  Radiotherapy (107)  ·  Erlotinib Hydrochloride (94)  ·  Gemcitabine (93)  ·  Cyclophosphamide (64)  ·  Etoposide (63)  ·  Bevacizumab (61)  ·  osimertinib (60)  ·  Cetuximab (59)

Sponsors

GlaxoSmithKline (189)  ·  AstraZeneca (121)  ·  National Cancer Institute (NCI) (114)  ·  Pfizer (104)  ·  Novartis Pharmaceuticals (65)  ·  M.D. Anderson Cancer Center (63)  ·  Memorial Sloan Kettering Cancer Center (53)  ·  Boehringer Ingelheim (51)  ·  Merck Sharp & Dohme LLC (48)  ·  Eli Lilly and Company (47)  ·  Bristol-Myers Squibb (37)  ·  Chiesi Farmaceutici S.p.A. (36)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (35)  ·  AbbVie (34)  ·  Amgen (32)

Countries

United States (2633)  ·  China (681)  ·  United Kingdom (498)  ·  Spain (380)  ·  Australia (368)  ·  Canada (308)  ·  France (292)  ·  Germany (275)  ·  South Korea (259)  ·  Japan (210)  ·  Belgium (194)  ·  Italy (176)  ·  Taiwan (167)  ·  Netherlands (158)  ·  Poland (98)

Results publications

PMID 34473343, PMID 33331662, PMID 37983082, PMID 24184147, PMID 35713300, PMID 36435633, PMID 37231296, PMID 22793945, PMID 31215818, PMID 31986264, PMID 33152467, PMID 36147329, PMID 39462179, PMID 40056080, PMID 42820295, PMID 16235359, PMID 16565429, PMID 16636091, PMID 16690673, PMID 17132052, PMID 17507545, PMID 18073405, PMID 19564349, PMID 20549206, PMID 20615924, PMID 21467219, PMID 21975749, PMID 22065672, PMID 22314182, PMID 22473314, PMID 22634621, PMID 22793939, PMID 23032745, PMID 23074435, PMID 23076942, PMID 23235687, PMID 23256721, PMID 23364286, PMID 2337756, PMID 23578144, PMID 23992090, PMID 24508444, PMID 24563632, PMID 24615270, PMID 24739759, PMID 24916507, PMID 25450456, PMID 25747273, PMID 26092545, PMID 26372465

NIH funding

2023 (71), 2016 (50), 2017 (48), 2015 (45), 2019 (38), 2018 (32), 2014 (27), 2025 (25), 2009 (13), 2008 (12), P30CA033572 (11), P30CA093373 (10), UM1CA186717 (8), P30CA138292 (7), P30CA016672 (6)